These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9342063)

  • 1. The influence of MT-2 tropism on the prognostic implications of the delta32 deletion in the CCR-5 gene.
    Bratt G; Sandström E; Albert J; Samson M; Wahren B
    AIDS; 1997 Oct; 11(12):1415-9. PubMed ID: 9342063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
    Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
    AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
    Sheppard HW; Celum C; Michael NL; O'Brien S; Dean M; Carrington M; Dondero D; Buchbinder SP
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):307-13. PubMed ID: 11873082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of a CCR5 defective allele in pediatric HIV-1 infection.
    Romiti ML; Colognesi C; Cancrini C; Mas A; Berrino M; Salvatori F; Orlandi P; Jansson M; Palomba E; Plebani A; Bertran JM; Hernandez M; de Martino M; Amoroso A; Tovo PA; Rossi P; Espanol T; Scarlatti G
    Mol Med; 2000 Jan; 6(1):28-36. PubMed ID: 10803406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.
    Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM
    AIDS; 1997 Dec; 11(15):1833-8. PubMed ID: 9412701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between a defective CCR-5 gene and progression to disease in HIV infection.
    Balfe P; Churcher Y; Penny M; Easterbrook PJ; Goodall RL; Galpin S; Gotch F; Daniels RS; McKeating JA
    AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1229-34. PubMed ID: 9764905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
    Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection.
    Zamarchi R; Indraccolo S; Minuzzo S; Coppola V; Gringeri A; Santagostino E; Vicenzi E; De Silvestro G; Biagiotti R; Baldassarre C; Chieco-Bianchi L; Amadori A
    AIDS Res Hum Retroviruses; 1999 Mar; 15(4):337-44. PubMed ID: 10082117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
    Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
    HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression.
    Xiao L; Rudolph DL; Owen SM; Spira TJ; Lal RB
    AIDS; 1998 Sep; 12(13):F137-43. PubMed ID: 9764773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of the CCR 5 gene in seronegative individuals exposed to human immunodeficiency virus (HIV).
    Rugeles MT; Solano F; Díaz FJ; Bedoya VI; Patiño PJ
    J Clin Virol; 2002 Jan; 23(3):161-9. PubMed ID: 11595595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review.
    Smoleń-Dzirba J; Rosińska M; Janiec J; Beniowski M; Cycoń M; Bratosiewicz-Wąsik J; Wąsik TJ
    AIDS Rev; 2017 Dec; 19(4):219-230. PubMed ID: 28534889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of early detection of HIV type 1 SI/CXCR4-using viruses in vertically infected children.
    Crudeli CM; Aulicino PC; Rocco CA; Bologna R; Mangano A; Sen L
    AIDS Res Hum Retroviruses; 2012 Jul; 28(7):685-92. PubMed ID: 22023092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
    Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
    J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
    Takácová M; Nogová P; Hábeková M; Staneková D
    Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 genotype and HIV-1 infection in perinatally-exposed infants.
    Mas A; Español T; Heredia A; Pedraza MA; Hernandez M; Caragol I; Fernando M; Bertran JM; Alcami J; Soriano V
    J Infect; 1999 Jan; 38(1):9-11. PubMed ID: 10090498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between CCR5
    Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
    Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.